IL104829A - Selection is based on a response to the expression and concentration of catalytic units - Google Patents

Selection is based on a response to the expression and concentration of catalytic units

Info

Publication number: IL104829A
Authority: IL; Israel
Prior art keywords: catalytic; substrate; moieties; viruses; phages
Prior art date: 1992-02-24

Application number

IL10482993A

Other languages

English (en)

Hebrew (he)

Other versions

IL104829A0 (en

Inventor

Gary F Blackburn

David M Simpson

Rodger G Smith

Mark T Martin

Michael J Darsley

Original Assignee

Igen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-02-24

Filing date

1993-02-23

Publication date

1999-04-11

1993-02-23 Application filed by Igen Inc filed Critical Igen Inc

1993-06-10 Publication of IL104829A0 publication Critical patent/IL104829A0/xx

1999-04-11 Publication of IL104829A publication Critical patent/IL104829A/en

Links

230000003197 catalytic effect Effects 0.000 title claims abstract description 373
238000006243 chemical reaction Methods 0.000 title abstract description 94
230000014509 gene expression Effects 0.000 title abstract description 21
239000000758 substrate Substances 0.000 claims abstract description 177
241000700605 Viruses Species 0.000 claims abstract description 169
238000000034 method Methods 0.000 claims abstract description 84
238000006555 catalytic reaction Methods 0.000 claims description 45
230000008569 process Effects 0.000 claims description 15
230000003993 interaction Effects 0.000 claims description 8
230000001965 increasing effect Effects 0.000 claims description 7
230000027455 binding Effects 0.000 abstract description 106
238000004519 manufacturing process Methods 0.000 abstract description 6
210000004027 cell Anatomy 0.000 description 150
239000003112 inhibitor Substances 0.000 description 96
239000003054 catalyst Substances 0.000 description 94
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 48
239000012528 membrane Substances 0.000 description 46
230000007062 hydrolysis Effects 0.000 description 38
238000006460 hydrolysis reaction Methods 0.000 description 38
150000001875 compounds Chemical class 0.000 description 36
230000007246 mechanism Effects 0.000 description 35
239000002245 particle Substances 0.000 description 34
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 30
150000002148 esters Chemical class 0.000 description 27
238000000926 separation method Methods 0.000 description 27
238000010828 elution Methods 0.000 description 25
239000011780 sodium chloride Substances 0.000 description 24
208000015181 infectious disease Diseases 0.000 description 23
230000033001 locomotion Effects 0.000 description 23
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 22
102000004190 Enzymes Human genes 0.000 description 22
108090000790 Enzymes Proteins 0.000 description 22
230000007306 turnover Effects 0.000 description 21
239000000243 solution Substances 0.000 description 17
238000001042 affinity chromatography Methods 0.000 description 16
239000000427 antigen Substances 0.000 description 16
239000000872 buffer Substances 0.000 description 16
230000000694 effects Effects 0.000 description 16
239000011159 matrix material Substances 0.000 description 15
239000003446 ligand Substances 0.000 description 14
239000000203 mixture Substances 0.000 description 14
102000036639 antigens Human genes 0.000 description 13
108091007433 antigens Proteins 0.000 description 13
238000003752 polymerase chain reaction Methods 0.000 description 13
108090000765 processed proteins & peptides Proteins 0.000 description 12
239000000376 reactant Substances 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 11
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
238000011534 incubation Methods 0.000 description 9
239000007790 solid phase Substances 0.000 description 9
108020004414 DNA Proteins 0.000 description 8
229920002684 Sepharose Polymers 0.000 description 8
238000001962 electrophoresis Methods 0.000 description 8
-1 for example Proteins 0.000 description 8
230000002101 lytic effect Effects 0.000 description 8
239000000126 substance Substances 0.000 description 8
230000003612 virological effect Effects 0.000 description 8
238000009792 diffusion process Methods 0.000 description 7
239000006249 magnetic particle Substances 0.000 description 7
239000007787 solid Substances 0.000 description 7
238000005406 washing Methods 0.000 description 7
206010010144 Completed suicide Diseases 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
108091005804 Peptidases Proteins 0.000 description 6
230000003053 immunization Effects 0.000 description 6
238000002649 immunization Methods 0.000 description 6
238000002955 isolation Methods 0.000 description 6
238000007790 scraping Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
102000035195 Peptidases Human genes 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
230000003321 amplification Effects 0.000 description 5
230000008859 change Effects 0.000 description 5
239000012141 concentrate Substances 0.000 description 5
238000010494 dissociation reaction Methods 0.000 description 5
230000005593 dissociations Effects 0.000 description 5
238000010931 ester hydrolysis Methods 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
239000000463 material Substances 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
150000003573 thiols Chemical class 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
230000004075 alteration Effects 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
229920001577 copolymer Polymers 0.000 description 4
230000008878 coupling Effects 0.000 description 4
238000010168 coupling process Methods 0.000 description 4
238000005859 coupling reaction Methods 0.000 description 4
230000000058 esterolytic effect Effects 0.000 description 4
230000001747 exhibiting effect Effects 0.000 description 4
230000005484 gravity Effects 0.000 description 4
230000005291 magnetic effect Effects 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
239000002609 medium Substances 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
235000019833 protease Nutrition 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000006722 reduction reaction Methods 0.000 description 4
230000007017 scission Effects 0.000 description 4
241001515965 unidentified phage Species 0.000 description 4
239000013598 vector Substances 0.000 description 4
FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 3
241001524679 Escherichia virus M13 Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108020005202 Viral DNA Proteins 0.000 description 3
QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
238000010276 construction Methods 0.000 description 3
238000011109 contamination Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000002427 irreversible effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002823 phage display Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
238000011084 recovery Methods 0.000 description 3
239000002356 single layer Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
241000894007 species Species 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000007704 transition Effects 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
101710132601 Capsid protein Proteins 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
241000701959 Escherichia virus Lambda Species 0.000 description 2
108090000371 Esterases Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
102000004317 Lyases Human genes 0.000 description 2
108090000856 Lyases Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
238000007259 addition reaction Methods 0.000 description 2
239000007801 affinity label Substances 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000006482 condensation reaction Methods 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000005684 electric field Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000006317 isomerization reaction Methods 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000008929 regeneration Effects 0.000 description 2
238000011069 regeneration method Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
150000007970 thio esters Chemical class 0.000 description 2
238000006276 transfer reaction Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
QKEYIYSLARKMSJ-UHFFFAOYSA-N 1-benzyl-3-(dimethylamino)-2,2-dimethyl-3,4-dihydronaphthalene-1,7-diol;hydrobromide Chemical compound Br.CC1(C)C(N(C)C)CC2=CC=C(O)C=C2C1(O)CC1=CC=CC=C1 QKEYIYSLARKMSJ-UHFFFAOYSA-N 0.000 description 1
QKCKCXFWENOGER-UHFFFAOYSA-N 2-phenyloxazol-5(4H)-one Chemical compound O1C(=O)CN=C1C1=CC=CC=C1 QKCKCXFWENOGER-UHFFFAOYSA-N 0.000 description 1
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
241001545522 Aguacate virus Species 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101100189378 Caenorhabditis elegans pat-3 gene Proteins 0.000 description 1
101100232929 Caenorhabditis elegans pat-4 gene Proteins 0.000 description 1
101100518972 Caenorhabditis elegans pat-6 gene Proteins 0.000 description 1
101100189379 Caenorhabditis elegans pat-9 gene Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000009025 Endorphins Human genes 0.000 description 1
108010049140 Endorphins Proteins 0.000 description 1
241000724791 Filamentous phage Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004195 Isomerases Human genes 0.000 description 1
108090000769 Isomerases Proteins 0.000 description 1
102000010954 Link domains Human genes 0.000 description 1
108050001157 Link domains Proteins 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000004879 Racemases and epimerases Human genes 0.000 description 1
108090001066 Racemases and epimerases Proteins 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
108010086019 Secretin Proteins 0.000 description 1
102100037505 Secretin Human genes 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
101150117115 V gene Proteins 0.000 description 1
BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
LKPVPUFUDFBNBZ-UHFFFAOYSA-N [3-oxo-2-phenyl-3-(pyridin-4-ylmethylamino)propyl] acetate Chemical compound C=1C=CC=CC=1C(COC(=O)C)C(=O)NCC1=CC=NC=C1 LKPVPUFUDFBNBZ-UHFFFAOYSA-N 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
230000009042 allosteric modification Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013522 chelant Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940090961 chromium dioxide Drugs 0.000 description 1
IAQWMWUKBQPOIY-UHFFFAOYSA-N chromium(4+);oxygen(2-) Chemical compound [O-2].[O-2].[Cr+4] IAQWMWUKBQPOIY-UHFFFAOYSA-N 0.000 description 1
AYTAKQFHWFYBMA-UHFFFAOYSA-N chromium(IV) oxide Inorganic materials O=[Cr]=O AYTAKQFHWFYBMA-UHFFFAOYSA-N 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000007247 enzymatic mechanism Effects 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000005294 ferromagnetic effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000010954 inorganic particle Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000002182 neurohumoral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
210000002729 polyribosome Anatomy 0.000 description 1
238000003825 pressing Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229960002101 secretin Drugs 0.000 description 1
OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
229920003048 styrene butadiene rubber Polymers 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000036964 tight binding Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physics & Mathematics (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Analytical Chemistry (AREA)
Biomedical Technology (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Crystallography & Structural Chemistry (AREA)
Plant Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Catalysts (AREA)
Saccharide Compounds (AREA)
Sampling And Sample Adjustment (AREA)

IL10482993A 1992-02-24 1993-02-23 Selection is based on a response to the expression and concentration of catalytic units IL104829A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US84164892A	1992-02-24	1992-02-24

Publications (2)

Publication Number	Publication Date
IL104829A0 IL104829A0 (en)	1993-06-10
IL104829A true IL104829A (en)	1999-04-11

Family

ID=25285377

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10482993A IL104829A (en)	1992-02-24	1993-02-23	Selection is based on a response to the expression and concentration of catalytic units

Country Status (12)

Country	Link
US (4)	US5631137A (fr)
EP (2)	EP0631633B1 (fr)
JP (1)	JP4125365B2 (fr)
KR (1)	KR100233950B1 (fr)
AT (1)	ATE221578T1 (fr)
AU (1)	AU675783B2 (fr)
CA (1)	CA2125405A1 (fr)
DE (1)	DE69332168T2 (fr)
ES (1)	ES2180543T3 (fr)
IL (1)	IL104829A (fr)
WO (1)	WO1993017124A1 (fr)
ZA (1)	ZA931263B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030069173A1 (en) *	1998-03-16	2003-04-10	Life Technologies, Inc.	Peptide-enhanced transfections
US6156541A (en) *	1995-07-21	2000-12-05	The Board Of Regents Of The University Of Nebraska	Compositions and methods for catalyzing hydrolysis of HIV gp120
EP0854933B1 (fr)	1995-09-07	2003-05-07	Novozymes A/S	Mise en evidence par des phages d'une activite enzymatique detersive
CA2249455A1 (fr) *	1996-03-26	1997-10-02	Amrad Operations Pty. Ltd.	Precurseurs d'anticorps catalytiques
AUPO930697A0 (en) *	1997-09-19	1997-10-09	Walter And Eliza Hall Institute Of Medical Research, The	Catalytic antibodies and a method of producing same
CN1314952A (zh) *	1998-08-19	2001-09-26	诺维信公司	直接通过底物再加载进行的酶活性筛选
AU2002308633A1 (en)	2001-05-09	2002-11-18	Monsanto Technology Llc	Metabolite transporters
EP1950305A1 (fr)	2001-05-09	2008-07-30	Monsanto Technology, LLC	Gènes tyr et utilisations associées
FR2831836B1 (fr) *	2001-11-08	2004-04-23	Inst Nat Polytech Grenoble	Procede de formation de sites catalytiques sur la surface d'un support
AU2003215388A1 (en) *	2002-02-22	2003-09-09	Purdue Research Foundation	Magnetic nanomaterials and methods for detection of biological materials
EP1532274A4 (fr) *	2002-06-28	2006-09-27	Purdue Research Foundation	Nanomateriaux magnetiques et procedes de detection de materiels biologiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3745285A (en) *	1983-11-29	1985-06-13	Igen, Inc.	Method of catalyzing chemical reactions
BE1006312A3 (fr) *	1991-11-29	1994-07-19	Univ Catholique Louvain	Procede de selection de microorganismes recombinants comportant a leur surface au moins une molecule a activite enzymatique.

1993
- 1993-02-23 IL IL10482993A patent/IL104829A/en not_active IP Right Cessation
- 1993-02-23 ZA ZA931263A patent/ZA931263B/xx unknown
- 1993-02-24 CA CA002125405A patent/CA2125405A1/fr not_active Abandoned
- 1993-02-24 WO PCT/US1993/001616 patent/WO1993017124A1/fr not_active Ceased
- 1993-02-24 ES ES93907001T patent/ES2180543T3/es not_active Expired - Lifetime
- 1993-02-24 JP JP51503693A patent/JP4125365B2/ja not_active Expired - Fee Related
- 1993-02-24 KR KR1019940702935A patent/KR100233950B1/ko not_active Expired - Fee Related
- 1993-02-24 AT AT93907001T patent/ATE221578T1/de not_active IP Right Cessation
- 1993-02-24 DE DE69332168T patent/DE69332168T2/de not_active Expired - Fee Related
- 1993-02-24 EP EP93907001A patent/EP0631633B1/fr not_active Expired - Lifetime
- 1993-02-24 AU AU37761/93A patent/AU675783B2/en not_active Ceased
- 1993-02-24 EP EP02001074A patent/EP1203824A3/fr not_active Withdrawn
1995
- 1995-01-24 US US08/377,495 patent/US5631137A/en not_active Expired - Lifetime
1996
- 1996-11-13 US US08/748,415 patent/US5891648A/en not_active Expired - Fee Related
- 1996-11-13 US US08/747,654 patent/US6121007A/en not_active Expired - Fee Related
1999
- 1999-01-21 US US09/235,353 patent/US6177270B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP4125365B2 (ja)	2008-07-30
AU675783B2 (en)	1997-02-20
US5631137A (en)	1997-05-20
US6121007A (en)	2000-09-19
EP1203824A2 (fr)	2002-05-08
EP0631633A1 (fr)	1995-01-04
AU3776193A (en)	1993-09-13
ZA931263B (en)	1993-11-02
US6177270B1 (en)	2001-01-23
IL104829A0 (en)	1993-06-10
CA2125405A1 (fr)	1993-09-02
EP0631633B1 (fr)	2002-07-31
US5891648A (en)	1999-04-06
ES2180543T3 (es)	2003-02-16
KR950700424A (ko)	1995-01-16
ATE221578T1 (de)	2002-08-15
EP0631633A4 (fr)	1998-02-25
KR100233950B1 (ko)	1999-12-15
DE69332168D1 (de)	2002-09-05
EP1203824A3 (fr)	2005-02-23
WO1993017124A1 (fr)	1993-09-02
DE69332168T2 (de)	2003-03-20
JPH07504090A (ja)	1995-05-11

Legal Events

Date	Code	Title
1999-08-17	FF	Patent granted
2000-06-01	KB	Patent renewed
2003-05-29	KB	Patent renewed
2007-06-17	KB	Patent renewed
2011-12-29	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
McCafferty et al.	1991	Phage-enzymes: expression and affinity chromatography of functional alkaline phosphatase on the surface of bacteriophage
US5270170A (en)	1993-12-14	Peptide library and screening method
Petrenko et al.	2003	Phage display for detection of biological threat agents
EP1200577B1 (fr)	2007-02-14	Selection in vitro et identification facultative de polypeptides a l'aide de porteurs a support solide
Smith et al.	1993	[15] Libraries of peptides and proteins displayed on filamentous phage
US6177270B1 (en)	2001-01-23	Reaction-based selection for expression of and concentration of catalytic moieties
JP2005538929A (ja)	2005-12-22	単一サンプルからの核酸及びタンパク質の単離方法
JPH09101306A (ja)	1997-04-15	標的蛋白質の親和性精製に有用なペプチドリガンドの選択のための組み合わせペプチドライブラリーのスクリーニング
Soumillion et al.	1994	Phage display of enzymes and in vitro selection for catalytic activity
CA2645194A1 (fr)	2002-05-02	Isolation de proteines de liaison ayant une haute affinite avec des ligands
Gaskin et al.	2001	Phage display combinatorial libraries of short peptides: ligand selection for protein purification
EP1105521A1 (fr)	2001-06-13	Criblage de l'activite enzymatique avec remplacement du substrat
JP4122694B2 (ja)	2008-07-23	タンパク質−ｄｎａ連結分子及びその利用
JP4125364B2 (ja)	2008-07-30	表面に，酵素活性を有する少なくとも１個の分子を含む組換え微生物を選択する方法
CN102373211A (zh)	2012-03-14	一组胰蛋白酶核酸适配子及其制备方法和应用
CN102373212A (zh)	2012-03-14	一组糜蛋白酶核酸适配子及其制备方法和应用
EP2791677B1 (fr)	2019-05-15	Stratégie générale pour le criblage de banques d'anticorps
AU764664B2 (en)	2003-08-28	Enzyme activity screen with substrate replacement
US20090203548A1 (en)	2009-08-13	Complex able to detect an analyte, method for its preparation and uses thereof
Ballinger	2004	Substrate phage display
Heinis et al.	2003	Calmodulin-tagged phage and two-filter sandwich assays for the identification of enzymatic activities